References
- Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum Vaccin Immunother. 2018;1–3. doi:10.1080/21645515.2018.1522468.
- Sanofi updates information on Dengue vaccine. [ accessed 2018 Oct 20]. http://mediaroom.sanofi.com/sanofiupdates information-on-dengue-vaccine/.
- Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Hj Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206. doi:10.1056/NEJMoa1506223.
- Dans AL, Dans LF, Lansang MAD, Silvestre MAA, Guyatt GH. Review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. J Clin Epidemiol. 2017. [First of series]. doi:10.1016/j.jclinepi.2017.11.019.
- Dengue vaccine: WHO position paper – July 2016. Weekly Epidemiological Record. 2016 Jul 29;vol. 91, 30. Geneva, World Health Organization, 2016. (pp. 349–364).
- Dengue vaccine: WHO position paper – Sept 2018. Weekly Epidemiological Record. 2018 Sep 7;vol. 93, 36. Geneva, World Health Organization, 2018. (pp. 457–476).
- Cooper LZ 1, Larson HJ, Katz SL. Protecting public trust in immunization. Pediatrics. 2008 Jul;122(1):149–153. doi:10.1542/peds.2008-0987.